NCT03119467 is a Phase 1 clinical trial of RP4010 in Lymphoma, sponsored by Rhizen Pharmaceuticals SA.

Who is sponsoring NCT03119467?

NCT03119467 is sponsored by Rhizen Pharmaceuticals SA.

What drugs are being tested in NCT03119467?

Interventions in NCT03119467: RP4010.

Is NCT03119467 still recruiting?

NCT03119467 is currently terminated. Last updated 27 December 2019.

Last reviewed 2019-12-27 · How we verify

NCT03119467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Terminated Phase 1 Last updated 27 December 2019

What this trial tests

Phase 1 trial testing RP4010 in Lymphoma in 21 participants. Terminated before completion.

Timeline

11 May 2017

Primary endpoint
29 November 2019

19 December 2019

Quick facts

Lead sponsor	Rhizen Pharmaceuticals SA
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	11 May 2017
Primary completion	29 November 2019
Estimated completion	19 December 2019
Sites	11 locations across United States, Australia

Drugs / interventions tested

RP4010 — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Rhizen Pharmaceuticals SA — full company profile →

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth.
Khan HY, Mpilla GB, Sexton R, Viswanadha S, et al · · 2020 · cited 37× · PMID 32235707 · DOI 10.3390/cancers12030750
Ca<sup>2+</sup> as a therapeutic target in cancer.
Gross S, Mallu P, Joshi H, Schultz B, et al · · 2020 · cited 25× · PMID 32723565 · DOI 10.1016/bs.acr.2020.05.003
Crosstalk between Ca<sup>2+</sup> Signaling and Cancer Stemness: The Link to Cisplatin Resistance.
Kouba S, Hague F, Ahidouch A, Ouadid-Ahidouch H. · · 2022 · cited 14× · PMID 36142596 · DOI 10.3390/ijms231810687
From Orai to E-Cadherin: Subversion of Calcium Trafficking in Cancer to Drive Proliferation, Anoikis-Resistance, and Metastasis.
Sharma A, Elble RC. · · 2020 · cited 14× · PMID 32575848 · DOI 10.3390/biomedicines8060169
Store-Operated Calcium Channels as Drug Target in Gastroesophageal Cancers.
Chang Y, Roy S, Pan Z. · · 2021 · cited 13× · PMID 34012400 · DOI 10.3389/fphar.2021.668730
Proton-sensing ion channels, GPCRs and calcium signaling regulated by them: implications for cancer.
Ji R, Chang L, An C, Zhang J. · · 2024 · cited 6× · PMID 38505262 · DOI 10.3389/fcell.2024.1326231
Roles of CRAC channel in cancer: implications for therapeutic development.
Khan HY, Mazahir I, Reddy S, Fazili F, et al · · 2020 · cited 6× · PMID 33728379 · DOI 10.1080/23808993.2020.1803062
ORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome.
Silva-Rojas R, Pérez-Guàrdia L, Simon A, Djeddi S, et al · · 2024 · cited 5× · PMID 38516893 · DOI 10.1172/jci.insight.174866

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Rhizen Pharmaceuticals SA trials

Trials by the same sponsor.

NCT06189209 — Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) · Phase 2 · recruiting
NCT05021900 — Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer · Phase 2 · completed
NCT05002868 — Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors · Phase 1 · completed
NCT05007236 — Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 · Phase 2 · completed
NCT04680429 — A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03119467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rhizen Pharmaceuticals SA
Last refreshed: 27 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03119467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing